Who
Steven M. Paul
Director
Company insider
Files Form 4 as: Director, Rapport Therapeutics; Director, Seaport Therapeutics; CSO and President of R&D, Karuna Therapeutics; Director, Sage Therapeutics; Director, Alnylam Pharmaceuticals; Chief Executive Officer, Voyager Therapeutics; Director, Sigma Aldrich; EVP, Science and Technology, Eli Lilly and.
In numbers
- Trades disclosed
- 287
- Buys
- 7
- Sells
- 26
- Bought
- $1.9M
- Sold
- $81.6M
- Companies
- 8
- Companies where not an officer
- 5
- First trade
- 23 Dec 2005
- Last trade
- 10 Jun 2026
- Last filed
- 10 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 10 Jun 2026filed 10 Jun 2026 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,200 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —67,031 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —210,526 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —210,526 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —67,031 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,258 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —991,192 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,258 at $0.00 | filing |
| 30 Apr 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —991,192 at $0.00 | filing |
| 12 Sep 2025filed 15 Sep 2025 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Bought | $693K28,284 at $24.50 | filing |
| 12 Sep 2025filed 15 Sep 2025 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Bought | $334K13,382 at $24.97 | filing |
| 17 Jun 2025filed 18 Jun 2025 | RAPP Rapport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,850 at $0.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $44.0M136,094 at $322.96 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $244.3M757,045 at $322.73 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $144.2M449,463 at $320.80 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $28.1M87,494 at $320.80 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $4.9M15,205 at $320.80 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $193.6M616,703 at $314.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Karuna Therapeuticsoption or derivative | SEC FORM 4 Code D | $22.0M71,121 at $309.98 | filing |
News
Can Eli Lilly's (LLY) Growth Machine Keep Delivering?LLY · insidermonkey.com · 18 Oct 2026NIH-Funded Study Finds GLP-1 Drugs Slow Aging In Mice, Boosting Outlook For Novo Nordisk (NYSE: NVO) And Eli Lilly (NYSE: LLY)LLY · foreignpolicyjournal.com · 18 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed EverythingLLY · aol.com · 16 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 1,147 Shares of Company StockRAPP · themarketsdaily.com · 9 Oct 2026Recent Research Analysts' Ratings Changes for Rapport Therapeutics (RAPP)RAPP · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Steven M. Paul; 8 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.